Top Page
Clarity Pharmaceuticals Ltd.
(Sydney:CU6)
Clarity Pharmaceuticals Ltd. (CU6) vs. iShares MSCI Australia ETF (EWA)
Clarity Pharmaceuticals Ltd. Business Overview & Revenue Model
Clarity Pharmaceuticals Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.78M | 11.51M | 9.80M | 6.46M | 3.20M | 2.79M |
| Gross Profit | 10.78M | 11.51M | 9.70M | 6.41M | 3.18M | 2.77M |
| EBITDA | -56.21M | -44.65M | -26.26M | -17.00M | -10.30M | -7.04M |
| Net Income | -48.70M | -42.32M | -24.60M | -23.75M | -10.22M | -6.95M |
Balance Sheet | ||||||
| Total Assets | 137.06M | 154.63M | 76.90M | 99.82M | 22.61M | 9.12M |
| Cash, Cash Equivalents and Short-Term Investments | 111.19M | 136.51M | 65.01M | 92.34M | 18.94M | 6.27M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 9.71M | 8.33M | 7.72M | 7.59M | 2.34M | 956.09K |
| Stockholders Equity | 127.35M | 146.30M | 69.18M | 92.24M | 20.28M | 8.16M |
Cash Flow | ||||||
| Free Cash Flow | -47.01M | -43.74M | -27.55M | -13.53M | -7.74M | -6.84M |
| Operating Cash Flow | -46.84M | -43.24M | -27.50M | -13.31M | -7.68M | -6.83M |
| Investing Cash Flow | -93.58M | -55.31M | 3.15M | -26.71M | -60.31K | -14.50K |
| Financing Cash Flow | 231.87M | 115.21M | 231.58K | 86.93M | 10.91M | 8.22M |
Clarity Pharmaceuticals Ltd. Technical Analysis
Clarity Pharmaceuticals Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $8.23B | 163.77 | 14.52% | ― | 55.85% | 893.42% | |
60 Neutral | HK$15.14B | 5.55 | -7.43% | 5.48% | 11.72% | -20.69% | |
54 Neutral | AU$215.44M | ― | -37.20% | ― | ― | 32.02% | |
53 Neutral | AU$671.88M | ― | -53.99% | ― | ― | -40.19% | |
46 Neutral | AU$66.72M | ― | -55.44% | ― | ― | 49.25% | |
36 Underperform | $2.65M | ― | -119.28% | ― | ― | 64.10% |
Clarity Pharmaceuticals Ltd. Corporate Events
Clarity Pharmaceuticals Ltd. has seen a change in the substantial holding of its shares by JPMorgan Chase & Co. and its affiliates, increasing their voting power from 6.32% to 7.33%. This shift indicates a growing interest and investment by JPMorgan in Clarity Pharmaceuticals, which could influence the company’s strategic decisions and market position. The change involves various transactions and securities lending agreements, reflecting active management of the investment by JPMorgan.
Clarity Pharmaceuticals Ltd. has announced a strategic refocus on high-priority programs, particularly the development of 64/67Cu-SAR-bisPSMA for prostate cancer and 64Cu-SARTATE for neuroendocrine tumors. The company has successfully advanced its SECuRE trial to the Cohort Expansion Phase, demonstrating promising safety and efficacy results. Clarity also presented significant findings at several world-leading conferences, highlighting its diagnostic portfolio’s ability to identify cancer lesions earlier than existing PSMA PET agents. These developments are expected to enhance Clarity’s market positioning and provide a substantial cash runway through to the second half of 2026.
JPMorgan Chase & Co. has increased its stake in Clarity Pharmaceuticals Ltd., a company known for its focus on developing radiopharmaceuticals for cancer treatment. The substantial holder’s voting power has risen from 5.23% to 6.32%, indicating a significant interest in Clarity’s operations and potential growth. This change in stake may impact Clarity’s market positioning and influence stakeholders’ perceptions of the company’s future prospects.
Clarity Pharmaceuticals has entered into a commercial-scale supply agreement with Nusano for copper-64 isotopes, which will bolster its existing network of suppliers in the US. This agreement is a strategic move to ensure a reliable and abundant supply of isotopes, supporting Clarity’s late-stage clinical trials and upcoming commercialization efforts. The partnership with Nusano, which is set to begin production in 2025, positions Clarity to overcome current market limitations and enhance its competitive edge in the oncology diagnostics market, particularly with its SAR-bisPSMA product for prostate cancer diagnosis.
Clarity Pharmaceuticals Ltd. has announced a significant change in its shareholder structure, with State Street Corporation and its subsidiaries becoming substantial holders. This development indicates a shift in the company’s ownership dynamics, potentially impacting its strategic decisions and market positioning. Stakeholders may observe changes in voting power and influence within the company, which could affect future business operations and investor confidence.
Clarity Pharmaceuticals has announced the treatment of the first participant in the Phase II Cohort Expansion of the SECuRE trial, using an enhanced formulation of 67Cu-SAR-bisPSMA. This phase follows the successful completion of the Dose Escalation Phase and aims to evaluate the safety and efficacy of this treatment in metastatic castration-resistant prostate cancer, particularly in the pre-chemotherapy setting. The trial includes a protocol amendment to test a combination therapy with enzalutamide, reflecting promising results from previous studies and expert consultations. The improved formulation offers room temperature stability, essential for large-scale manufacturing and commercialization, potentially reducing supply issues and shipment delays.
Clarity Pharmaceuticals has announced a change in its registered office and registry address to Liberty Place, Sydney, effective 14 April 2025. This move is part of the company’s ongoing efforts to enhance its operational capabilities and maintain its leadership position in the radiopharmaceutical industry, potentially impacting its stakeholders positively by improving treatment outcomes for cancer patients.
Clarity Pharmaceuticals Ltd. has announced that Vanguard Group, a prominent investment management company, has become a substantial holder in the company as of April 7, 2025. Vanguard Group now holds a 5.012% voting power in Clarity Pharmaceuticals, which is indicative of a significant investment and interest in the company’s operations. This development could potentially influence Clarity Pharmaceuticals’ market positioning and strategic decisions, given Vanguard’s substantial stake and its influence in the financial markets.
Clarity Pharmaceuticals Ltd announced the cessation of 6,620 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational and financial strategies.
JPMorgan Chase & Co. and its affiliates have become substantial holders in Clarity Pharmaceuticals Ltd, acquiring a 5.23% voting power in the company. This development signifies a notable investment by a major financial institution, potentially impacting Clarity Pharmaceuticals’ market positioning and stakeholder interests.
Clarity Pharmaceuticals has issued 25,000 fully paid ordinary shares following the exercise of options, without the need for disclosure under the Corporations Act. This move indicates Clarity’s compliance with relevant legal provisions and reflects its ongoing operational activities, potentially impacting its market position and stakeholder interests.
Clarity Pharmaceuticals Ltd has announced the quotation of 25,000 ordinary fully paid securities on the ASX, effective March 5, 2025. This move is part of the company’s strategy to enhance its market presence and provide additional value to its stakeholders by leveraging its innovative product offerings.
Clarity Pharmaceuticals has signed a supply agreement with The University of Queensland’s Australian Institute for Bioengineering and Nanotechnology for copper-64, which will support multiple clinical trials and pre-clinical programs. This agreement enhances Clarity’s capacity to provide innovative diagnostic options for prostate cancer and supports the development of theranostic programs, reflecting the company’s commitment to advancing cancer treatment and strengthening its collaborations within the Australian scientific community.
Clarity Pharmaceuticals Ltd. has released its interim report for 2025, highlighting key operational and corporate achievements, including advancements in clinical and regulatory developments. The report outlines significant progress in their product pipeline and manufacturing capabilities, which are expected to enhance the company’s market position and provide value to stakeholders.
Clarity Pharmaceuticals Ltd reported a 37% increase in its loss for the half-year ended 31 December 2024, amounting to $23.58 million, with no revenue growth and no dividends declared. Despite the financial setback, the company’s net tangible assets per ordinary security increased significantly from 20.2 cents to 39.7 cents, indicating a stronger asset base, which may offer some reassurance to stakeholders about the company’s long-term value.
Clarity Pharmaceuticals Ltd. has received Fast Track Designation from the US FDA for its Cu-67 SAR-bisPSMA product aimed at treating metastatic castration-resistant prostate cancer. This designation is a significant milestone, allowing Clarity to expedite the regulatory review process, potentially transforming prostate cancer treatment by addressing unmet medical needs and offering innovative therapeutic options. Positive preliminary results from the SECuRE study indicate the treatment’s efficacy in reducing PSA levels in heavily pre-treated patients, highlighting its potential in changing the prostate cancer treatment landscape.
Clarity Pharmaceuticals Ltd announced that the FDA has granted Fast Track Designation for its 64Cu-SAR-bisPSMA product, which aids in PET imaging of prostate cancer. Although the designation indicates FDA support, it doesn’t materially affect the company’s financial position but slightly increased the share price by 0.99%. The company emphasizes the importance of updating the market on such milestones, but notes that further clinical trials and regulatory approval are still required.
Clarity Pharmaceuticals has issued 98,625 fully paid ordinary shares following the exercise of options, without disclosure to investors as per the Corporations Act. This strategic move underscores Clarity’s compliance with relevant legal provisions, reflecting its ongoing commitment to financial transparency and potentially impacting its market positioning positively.
Clarity Pharmaceuticals Ltd announced a new issuance of 98,625 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) under the code CU6, effective February 4, 2025. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially affecting stakeholders by increasing liquidity and investor engagement.